공시 • Jul 17
Can B Corp. Files Form 15 Can B Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, no par value under the Securities Exchange Act of 1934, as amended. 공시 • Mar 29
Can B Corp. announced delayed annual 10-K filing On 03/28/2025, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 14
Can B Corp. announced delayed 10-Q filing On 11/13/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 29
Can B Files A Certificate on Form 15 with the U.S. Securities and Exchange Commission On October 25, 2024, Can B Corp. (‘Can B’) implemented a holding company reorganization (the ‘Nascent Merger’) pursuant to the Agreement and Plan of Merger (the ‘Merger Agreement’), dated as of October 23, 2024, among Can B, Nascent Pharma Holdings Inc. (‘Nascent’), and Nascent Merger Sub Inc. (‘Merger Sub’), which resulted in Nascent owning all of the outstanding capital stock of Can B. Pursuant to the Nascent Merger, Merger Sub, a direct, wholly owned subsidiary of Nascent and an indirect, wholly owned subsidiary of Can B, merged with and into Can B, with Can B surviving as a direct, wholly owned subsidiary of Nascent. Each share of each class of Can B stock issued and outstanding immediately prior to the Nascent Merger automatically converted into an equivalent corresponding share of Nascent stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Can B stock being converted. Accordingly, upon consummation of the Nascent Merger, Can B’s stockholders immediately prior to the consummation of the Nascent Merger became stockholders of Nascent. The stockholders of Can B will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Nascent Merger. In connection with the Nascent Merger, Can B notified the Financial Industry Regulatory Authority (‘FINRA’) that it planned to complete the Nascent Merger and, in connection therewith, requested that a new trading symbol be assigned to Nascent. FINRA requested that a new notice be submitted to FINRA after the Nascent Merger is complete. As a result, the change in issuer name and trading symbol on the OTCQB Market will not occur until FINRA completes the processing of the name change and assigns Nascent a trading symbol. On October 28, 2024, Can B filed a certificate on Form 15 with the U.S. Securities and Exchange Commission (the ‘Commission’) under the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’) requesting that Can B shares be deregistered under the Exchange Act, and that Can B’s reporting obligations under the Exchange Act be suspended (except to the extent of the succession of Nascent to the Exchange Act Section 12(g) registration and reporting obligations of Can B). 공시 • Aug 15
Can B Corp. announced delayed 10-Q filing On 08/14/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 18
Can B Corp. announced delayed 10-Q filing On 05/16/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Mar 30
Can B Corp. announced delayed annual 10-K filing On 03/29/2024, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 14
Can B Corp. announced delayed 10-Q filing On 11/13/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 12
Can B Corp. Announces its Move and Consolidation of its Pure Health Product Operations from Lacey, WA to Colorado Can B Corp. announced its move and consolidation of its Pure Health Product operations from Lacey, WA to Colorado. This furthers Can B’s corporate consolidations as it previously did with Miami and McMinville operations also relocating to Colorado. The move included relocating all of the Superfood products manufacturing, process, packaging, labeling, and raw materials/ingredients for Integrity Brands by Brooke Burke Body and other brands to the Company’s Fort Morgan facility on County Road 21, known as the “Budweiser Building.” Pure Health Products expects to have the Superfood production in full operation by mid-October 2023. The other production equipment, including bottling lines, capsule machines, tablet presses, coating machines, wet and dry pouch machines, and various packing sealing and coding equipment, was split into two segments between Hakala Research, LLC in Glen Rock, Wyoming, under a use agreement and CO Botanicals building on Energy Road in Fort Morgan, CO known as the “ICS Building.” This equipment will continue production of PHP’s white-label and brand-labeled tinctures, salves, roll-ons, oils, supplements, lotions, and related products, both with and without CBD. This equipment is expected to be operational by the end of October 2023 as the Company also has sufficient products in inventory to meet expected demand for 45-60 days at current usage. 공시 • May 16
Can B Corp. announced delayed 10-Q filing On 05/15/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Nov 15
Can B Corp. announced delayed 10-Q filing On 11/14/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 16
Can B Corp. announced delayed 10-Q filing On 08/15/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 17
Can B Corp. announced delayed 10-Q filing On 05/16/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 06
Can B Corp. announced delayed annual 10-K filing On 04/04/2022, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Aug 26
Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville. Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville on August 25, 2021.
Can B Corp. (OTCPK:CANB) completed the acquisition of 300,000 Square Foot Facility In McMinnville on August 25, 2021. 공시 • May 18
Can B Corp. announced delayed 10-Q filing On 05/17/2021, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 30
Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech. Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech on April 29, 2021.
Can B Corp. (OTCPK:CANB) completed the acquisition of Pharmacokinetics Tech on April 29, 2021. 공시 • Apr 02
Can B Corp. announced delayed annual 10-K filing On 03/31/2021, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Feb 19
Can B Corp Partners with Signature PR to Launch a New Premier Line Can B Corp. announced its partnership with Signature PR to initiate efforts for the launch of a new premier line. Under the leadership of Annamarie Seabright, Signature PR is developing an expansion plan into spas, salons, high-end retailers, hospitality services and others. 공시 • Feb 11
Can B Corp and Dr. Karl Zarse Launches ImmuneX2 Can B Corp. announced that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing immune system before need it. The certified organic twice a day AM/PM supplement is developed by a physician and prepackaged for convenient dosing. Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website. Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse’s ImmuneX2 label. Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2. 공시 • Sep 24
Can B Corp. announced that it has received $0.104 million in funding from EMA Financial LLC Can B Corp. (OTCPK:CANB) announced that it has entered into a securities purchase agreement with EMA Financial LLC to issue a 12% Convertible Promissory Note of the principal amount of $115,000 for gross proceeds of $104,000 on a best efforts basis, on June 15, 2020. The note is issued at an original issuance discount of $11,000 and bear an interest at 12% per year and matures on June 17, 2021. The note is convertible into shares at a price per share equal to 80% of the lowest closing bid price of the company’s common stock during the twenty trading days prior to the date of conversion. The company raised funding through exemption provided under Regulation D. 공시 • Sep 23
Can B Corp. announced that it has received $0.204545 million in funding from The EquiLux Group, LP On May 12, 2020, Can B Corp. (OTCPK:CANB) closed the transaction. The company issued securities pursuant to exemption provided under Regulation D. 공시 • Aug 15
Can B Corp. announced delayed 10-Q filing On 08/14/2020, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.